The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial

References

• Barouch DH. COVID-19 vaccines - immunity, variants, boosters. N Engl J Med. 2022;387(11):1011–1020. doi:10.1056/NEJMra2206573
   PubMed Web of Science ®Google Scholar
• Shrestha LB, Foster C, Rawlinson W, et al. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: implications for immune escape and transmission. Rev Med Virol. 2022;32(5):e2381. doi:10.1002/rmv.2381
   PubMed Web of Science ®Google Scholar
• Carabelli AM, Peacock TP, Thorne LG, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023;21(3):162–177.
   PubMed Web of Science ®Google Scholar
• Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399(10328):924–944. doi:10.1016/S0140-6736(22)00152-0
   PubMed Web of Science ®Google Scholar
• Andrews N, Stowe J, Kirsebom F, et al. COVID-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med. 2022;386(16):1532–1546. doi:10.1056/NEJMoa2119451
   PubMed Web of Science ®Google Scholar
• Costa Clemens SA, Weckx L, Clemens R, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet. 2022;399(10324):521–529. doi:10.1016/S0140-6736(22)00094-0
   PubMed Web of Science ®Google Scholar
• Li J, Hou L, Guo X, et al. Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial. Nat Med. 2022;28(2):401–409. doi:10.1038/s41591-021-01677-z
   PubMed Web of Science ®Google Scholar
• Li JX, Wu SP, Guo XL, et al. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Lancet Respir Med. 2022;10(8):739–748. doi:10.1016/S2213-2600(22)00087-X
   PubMed Web of Science ®Google Scholar
• Cheng SMS, Mok CKP, Leung YWY, et al. Neutralizing antibodies against the SARS-CoV-2 omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat Med. 2022;28(3):486–489. doi:10.1038/s41591-022-01704-7
   PubMed Web of Science ®Google Scholar
• Sritipsukho P, Khawcharoenporn T, Siribumrungwong B, et al. Real-life effectiveness of COVID-19 vaccine during the omicron variant-dominant pandemic: how many booster doses do we need? Emerg Microbes Infect. 2023;12(1):2174779. doi:10.1080/22221751.2023.2174779
   PubMed Web of Science ®Google Scholar
• Au WY, Cheung PP. Effectiveness of heterologous and homologous COVID-19 vaccine regimens: living systematic review with network meta-analysis. BMJ 2022;377:e069989. doi:10.1136/bmj-2022-069989
   PubMedGoogle Scholar
• Marra AR, Miraglia JL, Malheiros DT, et al. Effectiveness of heterologous coronavirus disease 2019 (COVID-19) vaccine booster dosing in Brazilian healthcare workers, 2021. Clin Infect Dis. 2023;76(3):e360–e366. doi:10.1093/cid/ciac430
   PubMed Web of Science ®Google Scholar
• China CDC. Situation of the novel coronavirus infection in China 2023. Available from: https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/. Accessed 14 Nov 2023.
   Google Scholar
• Xu K, Lei W, Kang B, et al. A novel mRNA vaccine, SYS6006, against SARS-CoV-2. Front Immunol. 2022;13:1051576. doi:10.3389/fimmu.2022.1051576
   PubMed Web of Science ®Google Scholar
• Chen GL, Qiu YZ, Wu KQ, et al. Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials. Hum Vaccin Immunother. 2023;19(3):2285089. doi:10.1080/21645515.2023.2285089
   PubMed Web of Science ®Google Scholar
• Wei LF, inventor. China National Intellectural Property Administration, assignee. Novel coronavirus mRNA vaccine against mutant strains. Chinese Invention Patent WO2023098679 (A1). 2023 Jun 8.
   Google Scholar
• Geng C, Zhou KF, Yan Y, et al. A preparation method for mRNA-LNPs with improved properties. J Control Release. 2023;364:632–643. doi:10.1016/j.jconrel.2023.11.017
   PubMed Web of Science ®Google Scholar
• Yang SL, Li Y, Dai LP, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021;21(8):1107–1119. doi:10.1016/S1473-3099(21)00127-4
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Development and licensure of vaccines to prevent COVID-19. Guidance for Industry 2020. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19. Accessed 14 Nov 2023.
   Google Scholar
• China National Medical Products Administration. Guidelines for grading adverse events in clinical trials of Prophylactic Vaccines (2019 edition). Available from: https://www.nmpa.gov.cn/yaopin/ypggtg/ypqtgg/20191231111901460.html. Accessed 14 Nov 2023.
   Google Scholar
• Naito T, Tsuchida N, Kusunoki S, et al. Reactogenicity and immunogenicity of BNT162b2 or mRNA-1273 COVID-19 booster vaccinations after two doses of BNT162b2 among healthcare workers in Japan: a prospective observational study. Expert Rev Vaccines. 2022;21(9):1319–1329. doi:10.1080/14760584.2022.2093722
   PubMed Web of Science ®Google Scholar
• Oda Y, Kumagai Y, Kanai M, et al. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet Infect Dis. 2023;S1473-3099(23)00650-3 Online ahead of print. doi:10.1016/S1473-3099(23)00650-3
   PubMedGoogle Scholar
• Dai L, Gao L, Tao L, et al. Efficacy and safety of the RBD-dimer-based COVID-19 vaccine ZF2001 in adults. N Engl J Med. 2022;386(22):2097–2111. doi:10.1056/NEJMoa2202261
   PubMed Web of Science ®Google Scholar
• Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA COVID-19 vaccine in a nationwide setting. N Engl J Med. 2021;385(12):1078–1090. doi:10.1056/NEJMoa2110475
   PubMed Web of Science ®Google Scholar
• Klein NP, Lewis N, Goddard K, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021;326(14):1390–1399. doi:10.1001/jama.2021.15072
   PubMed Web of Science ®Google Scholar
• Klastrup V, Staerke NB, Sogaard OS. Heterologous COVID-19 vaccination as a strategy to accelerate mass immunization. Clin Microbiol Infect. 2022;28(10):1316–1318. doi:10.1016/j.cmi.2022.06.032
   PubMed Web of Science ®Google Scholar
• Wang XY, Mahmood SF, Jin F, et al. Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial. Emerg Microbes Infect. 2022;11(1):1910–1919. doi:10.1080/22221751.2022.2088406
   PubMed Web of Science ®Google Scholar
• Pilz S, Theiler-Schwetz V, Trummer C, et al. SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity. Environ Res. 2022;209:112911. doi:10.1016/j.envres.2022.112911
   PubMed Web of Science ®Google Scholar
• Smolenov I, Han HH, Li P, et al. Impact of previous exposure to SARS-CoV-2 and of S-trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial. Lancet Infect Dis. 2022;22(7):990–1001. doi:10.1016/S1473-3099(22)00144-X
   PubMed Web of Science ®Google Scholar
• Nordstrom P, Ballin M, Nordstrom A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. Lancet Infect Dis. 2022;22(6):781–790. doi:10.1016/S1473-3099(22)00143-8
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. doi:10.1056/NEJMoa2035389
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577
   PubMed Web of Science ®Google Scholar
• Tanriover MD, Doganay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213–222. doi:10.1016/S0140-6736(21)01429-X
   PubMed Web of Science ®Google Scholar
• Bravo L, Smolenov I, Han HH, et al. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2022;399(10323):461–472. doi:10.1016/S0140-6736(22)00055-1
   PubMed Web of Science ®Google Scholar